Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Title A Phase 1 and Pharmacologic Study of MM-151 in Patients with Refractory Advanced Solid Tumors
Contact AD
Principal Investigator Alex Adjei, MD PhD
Study Number 204511
Phase1
Summary The main purpose of this study is to find the dose of MM-151 that does not cause unacceptable side effects ('maximum tolerated dose') or the doseof MM-151 that produces the best drug concentration level in the human body (recommended dose).  Researchers are also trying to learn about: The side effects of MM-151, How MM-151 is broken down in the human body, how safe and tolerable MM-151 is for patients.
Eligibility
  • See Clinicaltrials.gov listing for Eligibility criteria.
For more information about the clinical study go to Clinicaltrial.Gov
Source URL (retrieved on 05/25/2013 - 9:23am): http://www.roswellpark.org/clinical-trials/list/204511